What are the possible adverse reactions of Alpelisib?

Although Alpelisib-Piqray has significant efficacy in the treatment of HER2-negative, PIK3CA-mutated advanced breast cancer patients, it may also cause a series of adverse reactions. Understanding the characteristics of these adverse reactions and how to respond is critical to patient management.

The most common adverse reactions of apelix include hyperglycemia, rash, diarrhea, nausea, fatigue, and decreased appetite. Hyperglycemia is the most significant side effect of apelix, especially in patients with diabetes, and close monitoring of blood glucose levels may be necessary. Apelvis can cause insulin resistance or inhibit the secretion of insulin, resulting in increased blood sugar levels. During the treatment process, patients should check their blood sugar regularly and adjust their diet or medication according to the doctor's recommendations.

Skin rash is also a common side effect of Apelvis and usually manifests as a mild to moderate skin reaction. Patients can reduce symptoms with proper skin care and medication.

In addition, apelvis may cause gastrointestinal upset, such as nausea, vomiting, and diarrhea. These symptoms are usually related to the dose and duration of use of the drug. To relieve gastrointestinal discomfort, patients are advised to take Apelvis with food and use antiemetics as needed.

Other possible side effects of Apelvis include hematological adverse reactions, such as leukopenia, anemia, and thrombocytopenia. During treatment with Apelvis, patients need to undergo regular blood tests to ensure that these adverse reactions are detected and dealt with in a timely manner.

Although most adverse reactions of Apelvis are mild or moderate, some serious side effects may occur, such as pneumonia, abnormal liver function, and allergic reactions. Pneumonia is a serious side effect that may occur during the treatment of Apelvis, especially when it is used in combination with other immunosuppressive drugs. Patients need to seek medical treatment in time and receive corresponding treatment. In addition, Apelvis may also cause abnormal liver function, manifested as increased liver enzyme levels, and patients need to regularly monitor liver function.

Reference materials:https://www.ema.europa.eu/en/documents/product-information/piqray-epar-product-information_en.pdf